Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ceramides | 6 | 2000 | 36 | 0.340 |
Why?
|
| Apoptosis | 7 | 2000 | 1756 | 0.310 |
Why?
|
| Protein Kinase C | 3 | 1997 | 267 | 0.260 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 1990 | 151 | 0.240 |
Why?
|
| Phenanthridines | 4 | 1997 | 24 | 0.200 |
Why?
|
| T-Lymphocytes | 9 | 1995 | 1316 | 0.200 |
Why?
|
| Sphingomyelins | 2 | 1996 | 17 | 0.150 |
Why?
|
| Naphthalenes | 2 | 1996 | 41 | 0.150 |
Why?
|
| B-Lymphocytes | 3 | 1994 | 771 | 0.140 |
Why?
|
| Autoimmune Diseases | 3 | 1994 | 257 | 0.130 |
Why?
|
| Sphingosine | 2 | 1997 | 74 | 0.120 |
Why?
|
| Cell Communication | 4 | 1991 | 221 | 0.120 |
Why?
|
| Sleep Deprivation | 1 | 1996 | 133 | 0.120 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 4 | 1991 | 97 | 0.110 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 1994 | 44 | 0.110 |
Why?
|
| Sphingomyelin Phosphodiesterase | 4 | 2000 | 21 | 0.110 |
Why?
|
| Carcinoma | 1 | 1996 | 448 | 0.100 |
Why?
|
| Dexamethasone | 1 | 1994 | 351 | 0.090 |
Why?
|
| Antigen-Presenting Cells | 2 | 1990 | 145 | 0.090 |
Why?
|
| Mice | 18 | 2000 | 12537 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 1989 | 49 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 1996 | 625 | 0.090 |
Why?
|
| Immunoglobulin Idiotypes | 2 | 1988 | 12 | 0.080 |
Why?
|
| Interleukin-2 | 2 | 1996 | 248 | 0.080 |
Why?
|
| Benzophenanthridines | 4 | 1997 | 22 | 0.080 |
Why?
|
| Alkaloids | 4 | 1997 | 47 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 1989 | 432 | 0.080 |
Why?
|
| Thyroid Diseases | 1 | 1989 | 106 | 0.070 |
Why?
|
| Mice, Inbred CBA | 5 | 1996 | 52 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 1989 | 232 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1989 | 109 | 0.070 |
Why?
|
| H-2 Antigens | 1 | 1988 | 57 | 0.070 |
Why?
|
| Animals | 19 | 2000 | 28891 | 0.070 |
Why?
|
| Clone Cells | 6 | 1990 | 223 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1988 | 173 | 0.070 |
Why?
|
| Lymphocyte Activation | 5 | 1991 | 810 | 0.070 |
Why?
|
| Tumor Cells, Cultured | 4 | 2000 | 1049 | 0.070 |
Why?
|
| Enzyme Inhibitors | 4 | 2000 | 656 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 1989 | 467 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1989 | 488 | 0.060 |
Why?
|
| Lymphocytes | 3 | 1997 | 489 | 0.060 |
Why?
|
| Signal Transduction | 2 | 1996 | 3581 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 3 | 1995 | 17 | 0.050 |
Why?
|
| Cells, Cultured | 6 | 1997 | 2939 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2000 | 692 | 0.040 |
Why?
|
| Cytochrome c Group | 1 | 2000 | 82 | 0.040 |
Why?
|
| Epitopes | 3 | 1995 | 258 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 1994 | 3489 | 0.040 |
Why?
|
| CD3 Complex | 2 | 1989 | 136 | 0.040 |
Why?
|
| Lymphokines | 2 | 1989 | 75 | 0.040 |
Why?
|
| Thyroglobulin | 2 | 1996 | 59 | 0.040 |
Why?
|
| Hemolytic Plaque Technique | 2 | 1989 | 12 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 1989 | 1429 | 0.040 |
Why?
|
| Cell Division | 2 | 1997 | 705 | 0.040 |
Why?
|
| Immunization | 2 | 1996 | 165 | 0.030 |
Why?
|
| Thyroid Gland | 2 | 1990 | 281 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 1996 | 165 | 0.030 |
Why?
|
| Phosphorylcholine | 2 | 1988 | 27 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 1994 | 1124 | 0.030 |
Why?
|
| Immunization, Passive | 2 | 1988 | 75 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 1997 | 60 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1997 | 100 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 278 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 1996 | 165 | 0.030 |
Why?
|
| Thyroiditis | 1 | 1996 | 10 | 0.030 |
Why?
|
| Hydrolysis | 1 | 1996 | 146 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1996 | 411 | 0.030 |
Why?
|
| Cyclosporine | 1 | 1996 | 242 | 0.030 |
Why?
|
| Eating | 1 | 1996 | 165 | 0.030 |
Why?
|
| Spleen | 3 | 1996 | 439 | 0.030 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 1 | 1995 | 5 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1994 | 212 | 0.030 |
Why?
|
| Body Weight | 1 | 1996 | 460 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1996 | 317 | 0.030 |
Why?
|
| Receptors, Thyrotropin | 1 | 1995 | 48 | 0.030 |
Why?
|
| Lymphoma, B-Cell | 1 | 1996 | 111 | 0.030 |
Why?
|
| Cell Survival | 1 | 1997 | 1030 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 1997 | 553 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1996 | 1267 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 1996 | 385 | 0.020 |
Why?
|
| Gene Expression | 3 | 1995 | 1320 | 0.020 |
Why?
|
| Mitogens | 2 | 1990 | 61 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1994 | 201 | 0.020 |
Why?
|
| Myasthenia Gravis | 1 | 1993 | 83 | 0.020 |
Why?
|
| Lymphoma | 1 | 1994 | 271 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1995 | 713 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1995 | 684 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1997 | 1105 | 0.020 |
Why?
|
| Langerhans Cells | 1 | 1990 | 17 | 0.020 |
Why?
|
| Islets of Langerhans | 1 | 1994 | 559 | 0.020 |
Why?
|
| Rats | 1 | 1996 | 4155 | 0.020 |
Why?
|
| Fixatives | 1 | 1989 | 12 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1989 | 42 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1991 | 290 | 0.020 |
Why?
|
| Formaldehyde | 1 | 1989 | 53 | 0.020 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1989 | 110 | 0.020 |
Why?
|
| Lymphocyte Cooperation | 1 | 1989 | 5 | 0.020 |
Why?
|
| Immunoassay | 1 | 1989 | 100 | 0.020 |
Why?
|
| Ethanolamines | 2 | 2000 | 24 | 0.020 |
Why?
|
| Sheep | 1 | 1989 | 250 | 0.020 |
Why?
|
| Oleic Acids | 2 | 2000 | 26 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1989 | 40 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 1989 | 136 | 0.020 |
Why?
|
| Interleukins | 1 | 1989 | 134 | 0.020 |
Why?
|
| Endocannabinoids | 2 | 2000 | 27 | 0.020 |
Why?
|
| Antibodies | 1 | 1990 | 356 | 0.020 |
Why?
|
| Microsomes | 1 | 1988 | 35 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1989 | 231 | 0.020 |
Why?
|
| Cell Line | 2 | 1991 | 2537 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1989 | 380 | 0.020 |
Why?
|
| Graves Disease | 1 | 1988 | 36 | 0.020 |
Why?
|
| Polymers | 1 | 1989 | 220 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1989 | 254 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1988 | 218 | 0.020 |
Why?
|
| Immunity, Cellular | 1 | 1988 | 191 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 1987 | 23 | 0.020 |
Why?
|
| Antigens | 1 | 1988 | 231 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1988 | 320 | 0.020 |
Why?
|
| Female | 7 | 1996 | 50030 | 0.020 |
Why?
|
| HLA-DR Antigens | 3 | 1991 | 59 | 0.020 |
Why?
|
| Down-Regulation | 2 | 2000 | 526 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1988 | 695 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1996 | 688 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1997 | 830 | 0.010 |
Why?
|
| Liver | 1 | 1988 | 1238 | 0.010 |
Why?
|
| Phenotype | 1 | 1989 | 2578 | 0.010 |
Why?
|
| Combined Modality Therapy | 2 | 1997 | 1773 | 0.010 |
Why?
|
| Immunoglobulin G | 2 | 1996 | 481 | 0.010 |
Why?
|
| Time Factors | 3 | 1997 | 5580 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1995 | 3040 | 0.010 |
Why?
|
| Permeability | 1 | 2000 | 144 | 0.010 |
Why?
|
| Radiation, Ionizing | 1 | 2000 | 124 | 0.010 |
Why?
|
| Male | 3 | 1996 | 45865 | 0.010 |
Why?
|
| Ceramidases | 1 | 1997 | 4 | 0.010 |
Why?
|
| Amidohydrolases | 1 | 1997 | 18 | 0.010 |
Why?
|
| Endopeptidases | 1 | 1997 | 118 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1997 | 192 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1997 | 376 | 0.010 |
Why?
|
| Mitochondria | 1 | 2000 | 622 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1996 | 91 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1997 | 518 | 0.010 |
Why?
|
| Immunoglobulin Isotypes | 1 | 1995 | 33 | 0.010 |
Why?
|
| Humans | 7 | 1996 | 96109 | 0.010 |
Why?
|
| Autoantigens | 1 | 1996 | 139 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 1995 | 55 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1995 | 149 | 0.010 |
Why?
|
| CHO Cells | 1 | 1995 | 196 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1995 | 181 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1997 | 623 | 0.010 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 1995 | 99 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1995 | 220 | 0.010 |
Why?
|
| Cricetinae | 1 | 1995 | 542 | 0.010 |
Why?
|
| Streptozocin | 1 | 1994 | 56 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 1995 | 284 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 272 | 0.010 |
Why?
|
| Cell Death | 1 | 1995 | 264 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1995 | 207 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1993 | 40 | 0.010 |
Why?
|
| Transfection | 1 | 1995 | 908 | 0.010 |
Why?
|
| DNA Damage | 1 | 1995 | 392 | 0.010 |
Why?
|
| Leukemia | 1 | 1995 | 328 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1993 | 279 | 0.010 |
Why?
|
| Receptors, Nicotinic | 1 | 1993 | 134 | 0.010 |
Why?
|
| CD2 Antigens | 1 | 1991 | 22 | 0.010 |
Why?
|
| Autoantibodies | 1 | 1993 | 281 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 1996 | 667 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1991 | 84 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1991 | 82 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1995 | 2090 | 0.010 |
Why?
|
| Base Sequence | 1 | 1995 | 2344 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 1991 | 145 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1990 | 22 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1990 | 372 | 0.000 |
Why?
|
| Insulin | 1 | 1994 | 1190 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1995 | 2090 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 1562 | 0.000 |
Why?
|
| Epithelium | 1 | 1988 | 322 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1988 | 777 | 0.000 |
Why?
|
| Middle Aged | 1 | 1993 | 28369 | 0.000 |
Why?
|